Currently, there is no specific treatment or vaccine for SARS-CoV-2 available, some drugs are being investigated as treatment, but the effect is unknown. A strategy and other method used before, in coronavirus pandemic (SARS-CoV in 2003 and MERS-CoV in 2012), was the use of immune (convalescent) plasma. Passive administration of antibodies through convalescent plasma transfusion may offer the only short-term strategy available to confer immediate immunity and being a relative immediately resource available for treat COVID-19 disease. This research proposes the passive administration of antibodies through the transfusion of convalescent plasma, in patients with severe COVID-19 disease.
A randomized clinical trial comparing administration convalescent plasma to standard therapy
for severe COVID-19 disease. Patients will be randomized 1:1 in a single blind study. The
patients with SARS-CoV-2 PCR confirmed infection with pulmonary infiltrates and hypoxemia
will be screened and invited to participate. Our primary outcomes will be disease progression
and mortality, evaluate of ordinal Scale for Clinical Improvement and. (WHO)
Biological: Biological
An administration unit of 200 ml convalescent plasma intravenous infusion every 24 hours for two doses.
If a third dose of convalescent plasma is necessary, it may be used, as long as an evaluation of the research team is carried out.
Other Name: Convalescent plasma
Inclusion Criteria:
- O2 saturation <93%
- Radiographic evidence of moderate pneumonia according to Rale's classification.
- Acute respiratory distress syndrome (PaO2 / FiO2 <300 or SpO2 / FiO2 ≤ 315)
- Authorization to participate in the study and have informed consent letter, signed by
the patient or the person responsible for the patient in case of critical patients
(intubated)
Exclusion Criteria:
- Pregnant patients
- History of transfusion reactions
- Patients with congestive heart failure
- Patients with a history of chronic kidney failure on dialysis
- Patients with multiple organ failure
- Patients who does not accept or agree with the treatment.
Hospital Central Militar
Mexico City, Mexico
Carmen G Torres, MD, Principal Investigator
Hospital Central Militar